ObjectiveTo study the clinical manifestations, pathologic characteristics, imaging features, diagnosis and treatment of adenomas of extrahepatic bile duct.MethodsTwo cases of adenomas of extrahepatic bile duct in our hospital and 14 cases reported in the literatures were analyzed retrospectively.ResultsThe patients’(male 5, female 11) mean age was 58.4 years (range 21-85). The main manifestations included jaundice (n=11), abdominal pain (n=8),fever (n=6),dyspepsia (n=4),body weight loss (n=3) and claycolored stool (n=1). The locations of tumors were in the left hepatic duct (n=1), right hepatic duct (n=3), hepatic common bile duct(n=3）,the junction of cystic duct and common bile duct (n=1），distal common bile duct (n=8). The pathologic types were tubular adenomas (n=5), papillary (villous) adenomas (n=10),and mucous adenoma (n=1). All the patients underwent surgical therapy. The tumors were identified by postoperative histopathologic examination.ConclusionIt is difficult to correctly diagnose adenomas of extrahepatic bile duct before operation, because the clinical manifestations are usually atypical. The definite diagnosis should depend on histopathologic examination. It is the key to completely resect the tumors. Postoperative followup should be done on regular basis.
【Abstract】Objective To introduce the current research status, value and development future of Arg-Gly-Asp (RGD) peptides in diagnosis and treatment of neoplasms. Methods The current literatures on advances about RGD peptides in diagnosis and treatment of neoplasms were reviewed. Results RGD peptides, specificly recognizing and combining with integrin receptors, exist in extracellular matrix (ECM) of many kinds of organisms. After combining with integrin receptors, extrinsic RGD peptides can prevent tumor cells from adhering to ECM and migrating as the competitive inhibitor of intrinsic RGD peptides, suppress agiogenesis and induce tumor cells apoptosis, showing potential value of tumor specific imaging by targetal labelling neoplasms and treating tumors combining with other methods.Conclusion RGD peptides may be a new drug for diagnosis and treatment of neoplasms.
目的 探讨脾脏原发性肿瘤的诊断与治疗方法。方法 对我院1996～2003年收治的22例脾脏原发性肿瘤患者的临床资料进行回顾性分析。结果 22例患者临床症状无特异性，术前均行B超检查，发现脾大21例，提示脾脏占位病变19例，该19例行CT检查，均发现脾大并提示有占位病变。手术病检证实良性肿瘤12例，恶性肿瘤10例。22例患者均行脾切除，其中有5例行淋巴结清扫，2例行侵犯脏器联合切除。结论 脾脏原发性肿瘤术前诊断主要靠B超、CT，其治疗首选外科手术。
The nucleic acid adapters of tumor serum markers are oligonucleotide molecules with high specificity and high affinity with tumor serum markers obtained by in vitro screening with systematic evolution of ligands by exponential enrichment (SELEX). Researchers take the advantage of the nucleic acid adapter to explore new tumor serum markers that have more diagnostic value for tumor diagnosis. Recently, some achievements have been achieved in the research of liver cancer and stomach cancer. This paper has reviewed nucleic acid adapter and its research in the serum tumor marker screening, and discussed the value of the nucleic acid adapter of serum tumor markers in the diagnosis, as well as current problems existing in the research. This paper is very useful to help people better understand the screening of nucleic acid adapters of tumor serum markers, and to provide help in discovering new tumor serum markers.
Nucleic acid aptamer is an oligonucleotide sequence screened by the exponential enrichment ligand system evolution technology (SELEX). Previous studies have shown that nucleic acid aptamer has a good application prospect in tumor diagnosis and treatment. Therefore, we reviewed the selection and identification of nucleic acid aptamer of lung cancer cells in recent years, and discussed the effect of aptamer as targeting drugs and targeting vectors on the diagnosis of tumors, which provide a new idea for early diagnosis and treatment of tumor.